Commercial products for individual and family coverage available through MNsure, including UCare Individual & Family Plans and UCare Individual & Family Plans with M Health Fairview.
UCare Medicare Plans, UCare Medicare Plans with M Health Fairview and North Memorial, UCare Medicare Group Plans and EssentiaCare.
UCare Connect + Medicare and Minnesota Senior Health Options (MSHO)
UCare Connect (Special Needs BasicCare), Minnesota Senior Care Plus (MSC Plus), MinnesotaCare (MnCare), Prepaid Medical Assistance Program (PMAP)
The Pharmacy and Therapeutics Committee, a group of practicing physicians and pharmacists, meets up to six times per year to recommend medication inclusion or exclusion to our formularies. The Pharmacy and Therapeutics Committee evaluates drugs based on clinical evidence and efficacy (drug monographs, peer reviewed literature, compendia resources), therapeutic guidelines, medication safety and comparable data to other therapeutic alternatives. This committee reviews all new drugs approved by the FDA, new generics, new dosage forms, new indications as well as regular therapeutic class reviews and annual review of all utilization management criteria.
Care Continuum, a subsidiary of Express Scripts
Online (ePA): ExpressPAth Portal at www.express-path.com/.
612-676-3300 or 1-888-531-1493
Hours: 8 a.m. to 5 p.m., Monday through Friday
UCare is temporarily changing prior authorization and notification requirements for certain post-acute care services effective for dates of services April 20, 2020, to June 30, 2020, in response to COVID-19.
On May 28, 2020, the Food and Drug Administration (FDA) announced they requested five drug manufacturers to voluntarily recall their Metformin Extended-Release (ER) products from the marketplace due to higher than acceptable levels of N-Nitrosodimethylamine (NDMA). Impacted manufacturers have submitted recall notices to the FDA.
Read the June 11 Provider Bulletin for details on which manufacturers are affected, what prescribers should do and how UCare is notifying impacted members.
Providers should transition to the new forms by July 1.
On Sept. 21, 2020, the FDA announced a voluntary recall of all unexpired albuterol inhalers manufactured by Perrigo. This recall is to the retail pharmacy level. The FDA urges patients to continue using the inhaler they have on hand. UCare’s pharmacy department is contacting impacted members and their providers.
Read the October 6 Bulletin for more information.
Receive our monthly newsletter and bulletins with timely updates from UCare right to your inbox.SIGN UP